老年适合患者原发性弥漫大B细胞中枢神经系统淋巴瘤的高剂量化疗联合自体造血干细胞移植(MARTA):单臂2期试验
MARTA是一项在德国15家研究医院开展的前瞻性单臂2期研究,纳入65岁及以上、新诊断未经治疗且适合高剂量化疗联合自体造血干细胞移植的原发性弥漫大B细胞中枢神经系统淋巴瘤患者。诱导治疗为两个21天周期的甲氨蝶呤、阿糖胞苷和利妥昔单抗,随后行高剂量化疗联合自体造血干细胞移植。51例可分析患者12个月无进展生存率为58.8%(80%CI 48.9-68.2;95%CI 44.1-70.9),主要疗效阈值未达到。
要点
- 65岁及以上适合的PCNSL患者接受短程诱导后高剂量化疗联合自体HSCT,12个月无进展生存率58.8%。
- 诱导期间最常见3-5级毒性为血小板减少和白细胞减少,各见于52/54例(96%)。
- 治疗相关死亡3/54例(6%),均因感染并发症。
核心结论
- 虽然主要疗效阈值未达到,但短程诱导后高剂量化疗联合自体造血干细胞移植在经选择的老年PCNSL患者中具有活性,可作为对比试验的基准。
研究设计与样本
- MARTA为前瞻性单臂2期研究,在德国15家研究医院开展,纳入65岁及以上新诊断未经治疗、ECOG体能状态0-2且适合高剂量化疗联合自体HSCT的PCNSL患者。
- 诱导治疗为两个21天周期:第1天静脉甲氨蝶呤3.5 g/m2,第2、3天静脉阿糖胞苷2 g/m2每日两次,第0、4天静脉利妥昔单抗375 mg/m2。
- 随后高剂量化疗:第-8天静脉利妥昔单抗375 mg/m2,第-7、-6天静脉白消安3.2 mg/kg,第-5、-4天静脉塞替派5 mg/kg,联合自体HSCT。
- 主要终点为符合入组标准并开始治疗的全部患者的12个月无进展生存率;2017年11月28日至2020年9月16日共54例患者开始诱导治疗,51例纳入全分析集。
主要发现
- 中位年龄71岁(IQR 68-75),女性27例(53%),男性24例(47%)。
- 中位随访23.0个月(IQR 16.8-37.4),51例中23例(45%)出现进展、复发或死亡。
- 12个月无进展生存率为58.8%(80%CI 48.9-68.2;95%CI 44.1-70.9)。
- 诱导治疗期间最常见3-5级毒性为血小板减少和白细胞减少,各见于54例中的52例(96%)。
- 高剂量化疗联合自体HSCT期间最常见3-5级毒性为白细胞减少,见于37例中的37例(100%);治疗相关死亡3/54例(6%),均因感染并发症。
临床怎么用
- 作者认为短程诱导后高剂量化疗联合自体HSCT在经选择的老年PCNSL患者中具有活性,可作为对比试验的基准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT) in older patients with PCNSL. METHODS: MARTA was a prospective, single-arm, phase 2 study done at 15 research hospitals in Germany. Patients aged 65 years or older with newly diagnosed, untreated PCNSL were enrolled if they had an Eastern Cooperative Oncology Group performance status of 0-2 and were fit for high-dose chemotherapy and autologous HSCT. Induction treatment consisted of two 21-day cycles of high-dose intravenous methotrexate 3·5 g/m2 (day 1), intravenous cytarabine 2 g/m2 twice daily (days 2 and 3), and intravenous rituximab 375 mg/m2 (days 0 and 4) followed by high-dose chemotherapy with intravenous rituximab 375 mg/m2 (day -8), intravenous busulfan 3·2 mg/kg (days -7 and -6), and intravenous thiotepa 5 mg/kg (days -5 and -4) plus autologous HSCT. The primary endpoint was progression-free survival at 12 months in all patients who met eligibility criteria and started treatment. The study was registered with the German clinical trial registry, DRKS00011932, and recruitment is complete. FINDINGS: Between Nov 28, 2017, and Sept 16, 2020, 54 patients started induction treatment and 51 were included in the full analysis set. Median age was 71 years (IQR 68-75); 27 (53%) patients were female and 24 (47%) were male. At a median follow-up of 23·0 months (IQR 16·8-37·4), 23 (45%) of 51 patients progressed, relapsed, or died. 12-month progression-free survival was 58·8% (80% CI 48·9-68·2; 95% CI 44·1-70·9). During induction treatment, the most common grade 3-5 toxicities were thrombocytopenia and leukopenia (each in 52 [96%] of 54 patients). During high-dose chemotherapy and autologous HSCT, the most common grade 3-5 toxicity was leukopenia (37 [100%] of 37 patients). Treatment-related deaths were reported in three (6%) of 54 patients, all due to infectious complications. INTERPRETATION: Although the primary efficacy threshold was not met, short induction followed by high-dose chemotherapy and autologous HSCT is active in selected older patients with PCNSL and could serve as a benchmark for comparative trials. FUNDING: Else Kröner-Fresenius Foundation, Riemser Pharma, and Medical Center-University of Freiburg.
引用
- Schorb E, Isbell LK, Kerkhoff A, et al. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024. PMID: 38301670. doi:10.1016/S2352-3026(23)00371-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。